Apollo Therapeutics Raises $226.5M in Series C Financing

UK's Apollo Therapeutic aims to advance its pipeline programs through clinical development and provide further support for its drug discovery and development initiatives.

UK-based biopharmaceutical company, Apollo Therapeutics has successfully raised $226.5 million in Series C funding. This latest Series C financing significantly adds to the $195 million previously raised by the company.

The funding round led by Patient Square Capital, saw participation from new investors including M&G plc along with its existing investor Rock Springs Capital.

The Cambridge, UK-, Boston, MA and Chicago, IL-based biopharmaceutical company, aims to utilise the funds in two folds. First, to advance their pipeline programs through clinical development and to provide further support for their drug discovery and development initiatives, which are based on breakthroughs in basic medical research conducted at their partner institutions.

Second, Apollo Therapeutics plans to explore licensing or acquiring additional clinical-stage programs that align with rigorous selection criteria.

Led by Dr. Richard Mason, CEO, Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating basic medical research into treatments. They employ a portfolio-based model that centres around a centralised management team comprising experts in capital allocation, pharmaceutical R&D, manufacturing, commercial strategy, fundraising, and business development. This team oversees a diverse portfolio of therapeutic programs, each led by a dedicated asset leader.

Currently, Apollo Therapeutics collaborates with renowned partner institutions such as The University of Cambridge, Imperial College London, University College London, King's College London, and The Institute of Cancer Research. The company operates in Cambridge, UK, as well as Boston and Chicago in the USA.